

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11)

EP 1 016 660 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
05.07.2000 Bulletin 2000/27

(51) Int. Cl. 7:

C07D 209/42, C07D 307/79,
C07D 333/38, C07D 333/68,
A61K 31/34, A61K 31/38,
A61K 31/40

(21) Application number: 98941734.0

(22) Date of filing: 07.09.1998

(86) International application number:
PCT/JP98/03991

(87) International publication number:
WO 99/15502 (01.04.1999 Gazette 1999/13)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: 19.09.1997 JP 25400297


(71) Applicant: SHIONOGI & CO., LTD.
Osaka-shi, Osaka 541-0045 (JP)

(72) Inventor: HONMA, Tsunetoshi
Nara 630-0239 (JP)

(74) Representative:
Baverstock, Michael George Douglas et al
BOULT WADE TENNANT,
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT (GB)

(54) COMPOUNDS HAVING 2.2.1]BICYCLO SKELETON

(57) This invention provides novel compounds which are dually antagonistic to TXA₂ and PGD₂ receptors and pharmaceutical compositions containing them. They are useful for treating, for example, systemic mastocytosis and disorders of systemic mast cell activation as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, and inflammation. In detail, this invention provides a compound of the formula (I):



a pharmaceutically acceptable salt thereof, or a hydrate thereof.

BEST AVAILABLE COPY

Description**Technical Field**

5 [0001] This invention relates to compounds having a [2. 2. 1] bicyclo skeleton, and pharmaceutical compositions containing them antagonistic to both thromboxane A₂ and prostaglandin D₂.

Background Art

10 [0002] Some compounds having a [2.2.1] bicyclo skeleton similar to the compounds of the present invention have been described in Japanese Patent Publication (Kokoku) No. 53295/1991. In this publication, it is explained that the compounds are useful as thromboxane A₂ (TXA₂) antagonists. TXA₂ has been known to have various activities such as platelet aggregation, thrombogenesis, etc. The TXA₂ antagonists which antagonize TXA₂ have therefore been considered to be useful as anti-thrombotic agents as well as medicines for treating myocardial infarction or asthma.

15 [0003] Further, other compounds having a [2.2.1] bicyclo skeleton similar to the compounds of the present invention have been described in WO97/00853. In this publication it is described that the compounds are useful as prostaglandin D₂(PGD₂) antagonists. PGD₂ is a major prostanoid released from mast cells in which it is produced through PGG₂ and PGH₂ from arachidonic acid by the action of cyclooxygenase activated by immunological or unimmunological stimulation. PGD₂ has various potent physiological and pathological activities. For example, PGD₂ can cause strong contraction of the smooth muscle of the bronchus so as to lead to bronchial asthma, and in a systemic 20 allergic state, it dilates the peripheral vessels so as to cause an anaphylactic shock.

Accordingly, PGD₂ antagonists are useful for the improvement of conditions caused by excessive production of PGD₂, particularly as drugs for treating diseases involved with mast cell dysfunction, for example, systemic mastocytosis and disorder of systemic mast cell activation as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, atopic dermatitis, alimentary allergy, cerebrovascular disorder, ischemic reperfusion injury, and inflammation.

25 [0004] As shown above, PGD₂ antagonists have a quite different character from that of TXA₂ antagonists in the site of action, mechanism of action, and indication thereof.


30 [0005] On the other hand, TXA₂ and PGD₂ dual antagonistic compounds could be useful as therapeutic agents for treating various diseases caused by TXA₂ or PGD₂. For example, it is known that TXA₂ has a strong activity for tracheal contraction and respiratory anaphylaxia, and recently known that PGD₂ has activity for infiltration of eosinophils. From these discoveries, TXA₂ and PGD₂ are thought to be one of the causative substances of the pathopoeisis and advance of asthma, thus the dual antagonistic compounds are expected to be possible more useful agents for treating asthma than any of the known antagonists. Further, in the case of allergic rhinitis, it is recognized that TXA₂ and PGD₂ cause swelling of nasal mucosa through the aggravation of vascular permeability, and PGD₂ induces nasal blockage 35 through enlargement of vascular volume. It is therefore expected to be able to develop drugs having dual antagonistic activity.

35 [0006] As shown above, the compounds having a dual antagonistic activity are expected to be used for many indications and to exhibit excellent new therapeutic effects which have not yet been known.

40 Disclosure of Invention

[0007] The present inventors have studied intensively to develop PGD₂ receptor antagonists (blockers) specific to the PGD₂ receptor, and discovered a new series of compounds which are useful not only as PGD₂ receptor antagonists but also as TXA₂ receptor antagonists and have high safety, whereby accomplishing the present invention.

45 [0008] Accordingly, the present invention provides a compound of the formula (I):



50 wherein R is an optionally substituted monocyclic or condensed heterocycle, provided that R is not an optionally substituted dibenzofuryl, X is hydrogen or an alkyl, and the double bond has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a TXA₂ and PGD₂ antagonistic pharmaceutical compositions comprising them, preferably a pharmaceutical composition for treating asthma or nasal blockage comprising them.

Best Mode for Carrying Out the Invention

[0009] In the above formula, "optionally substituted monocyclic or condensed heterocycle" for R means a 5-7 membered ring containing one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring, or such a heterocycle as condensed with one or more carbocycle or other heterocycle and both rings may have a bond and substituent(s) at any substitutable position(s), provided that R does not include an optionally substituted dibenzofuryl.

[0010] The term "carbocycle or other heterocycle" means a 5-7 membered ring which may have one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring, or a condensed ring consisting of two or more of such rings.

[0011] Examples of "monocyclic or condensed heterocycle" include pyrrolidinyl (e.g., 2-pyrrolidinyl), pyrrolyl (e.g., 2-pyrrolyl, 3-pyrrolyl), piperidinyl (e.g., 3-piperidinyl, 4-piperidinyl), pyridyl (e.g., 3-pyridyl, 4-pyridyl), pyrazolyl (e.g., 3-pyrazolyl), imidazolyl (e.g., 2-imidazolyl, 3-imidazolyl), piperazinyl (e.g., 2-piperazinyl), pyrimidinyl (e.g., 4-pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), indolyl (e.g., 2-indolyl, 3-indolyl), carbazolyl (e.g., 3-carbazolyl), benzoimidazolyl (e.g., 2-benzoimidazolyl), indazolyl (e.g., 3-indazolyl), quinolyl (e.g., 8-quinolyl), isoquinolyl (e.g., 3-isoquinolyl), tetrahydrofuryl (e.g., 3-tetrahydrofuryl), furyl (e.g., 2-furyl, 3-furyl), benzofuryl (e.g., 2-benzofuryl, 3-benzofuryl), tetrahydrothienyl (e.g., 2-tetrahydrothienyl, 3-tetrahydrothienyl), thienyl (e.g., 2-thienyl, 3-thienyl), benzothienyl (e.g., benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl), dibenzothienyl (e.g., 2-dibenzothienyl, 3-dibenzothienyl), tetrahydronaphthothienyl (e.g., 1,2,3,4-tetrahydronaphthothienyl), naphthothienyl (e.g., naphtho[2,3-b]thienyl, naphtho[1,2-b]thienyl), oxazolyl (e.g., 2-oxazolyl), isoxazolyl (e.g., 4-isoxazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl), isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl), and the like.

[0012] The preferable embodiment of "monocyclic or condensed heterocycle" is an aromatic monocyclic or condensed heterocycle such as pyrrolyl (e.g., 2-pyrrolyl, 3-pyrrolyl), pyridyl (e.g., 3-pyridyl, 4-pyridyl), pyrazolyl (e.g., 3-pyrazolyl), imidazolyl (e.g., 2-imidazolyl, 3-imidazolyl), pyrimidinyl (e.g., 4-pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), indolyl (e.g., 2-indolyl, 3-indolyl), carbazolyl (e.g., 3-carbazolyl), benzoimidazolyl (e.g., 2-benzoimidazolyl), indazolyl (e.g., 3-indazolyl), quinolyl (e.g., 8-quinolyl), isoquinolyl (e.g., 3-isoquinolyl), furyl (e.g., 2-furyl, 3-furyl), benzofuryl (e.g., 2-benzofuryl, 3-benzofuryl), thienyl (e.g., 2-thienyl, 3-thienyl), benzothienyl (e.g., benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl), dibenzothienyl (e.g., 2-dibenzothienyl, 3-dibenzothienyl), tetrahydronaphthothienyl (e.g., 1,2,3,4-tetrahydronaphthothienyl), naphthothienyl (e.g., naphtho[2,3-b]thienyl, naphtho[1,2-b]thienyl), oxazolyl (e.g., 2-oxazolyl), isoxazolyl (e.g., 4-isoxazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl), isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl), and the like.

[0013] The present invention includes a compound of the formula (I) wherein R is an optionally substituted monocyclic or condensed heterocycle containing only a sulfur atom(s) as hetero atom.

[0014] "Optionally substituted monocyclic or condensed heterocycle containing only a sulfur atom(s) as hetero atom" includes the following groups which are optionally substituted:

35


40

45


50

55


EP 1 016 660 A1




5




10



15



20



25

[0015] The substituents of "optionally substituted monocyclic or condensed heterocycle" include a substituent selected from an alkyl, an alkenyl, an acyl, an alkoxy, an alkylthio, an acyloxy, hydroxy, a halogen, nitro, and a substituted or unsubstituted amino. The substituent may bind to one to three of any substitutable positions on the ring.

[0016] Throughout the specification, the term "alkyl", used itself or combined with other terms, means a C1-C8 straight or branched chain alkyl or a C3-C8 cycloalkyl, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl, i-pentyl, n-hexyl, n-heptyl, n-octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

[0017] Throughout the specification, the term "alkenyl", used itself or combined with other terms, means a C2-C8 straight or branched chain alkenyl or a C3-C8 cycloalkenyl, which has one or more double bonds, for example, vinyl, 1-propenyl, 2-propenyl, i-propenyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, and the like.

[0018] Throughout the specification, the term "acyl", used itself or combined with other terms, means an alkylcarbonyl or an alkenylcarbonyl, for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, acryloyl, metaacryloyl and the like.

[0019] Throughout the specification, the term "alkoxy", used itself or combined with other terms, means an alkoxy, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, and the like.

[0020] Examples of "alkylthio" include methylthio, ethylthio, propylthio, and the like.

[0021] Examples of "acyloxy" include acetoxy, propionyloxy, butyryloxy, isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy, metaacryloyloxy, and the like.



[0022] The term "halogen" means fluorine, chlorine, bromine, and iodine.

[0023] The term "substituted or unsubstituted amino" means an optionally substituted amino, and the substitutions include, for example, alkyl, alkenyl, acyl, alkoxy carbonyl, or alkylsulfonyl, and the like. Examples of the alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, n-butoxycarbonyl, t-butoxycarbonyl, and the like. Examples of the alkylsulfonyl include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, i-propylsulfonyl, n-butylsulfonyl, t-butylsulfonyl, and the like.

[0024] The preferable embodiment of "optionally substituted monocyclic or condensed heterocycle" is a monocyclic or condensed aromatic heterocycle, which is not substituted at all or substituted with hydroxy or halogen, and contains a sulfur atom only as a hetero atom.


[0025] In the above formula(I), preferably R is a group represented by the following formula:

55




15 wherein Y and Z each is independently hydrogen, hydroxy, or a halogen.

[0026] More preferably R is represented by the formula:



25 wherein Y and Z are as defined above.

[0027] The compounds of the present invention can be any of the following stereo isomers of the [2.2.1] bicyclo skeleton; thus the present invention includes all of them and the optional mixtures thereof. Specifically, the bond binding to the bicyclic ring is in R configuration or S configuration, and all of the stereo isomers (diastereomer, epimer, enantiomer, and the like), racemates, and optional mixtures thereof are included in the present invention.




[0028] In these stereo isomers, the most preferable is a compound having the skeleton of the formula:




50 [0029] Moreover, the α chain of the compound of the present invention can be in Z configuration or E configuration; thus a compound having any of the configurations and the mixtures thereof are included in the present invention.

[0030] As understood from the above explanations, a preferable embodiment is a compound of the formula (I):



5 wherein R is a group of the formula:



wherein Y and Z each is independently hydrogen, hydroxy, or a halogen, and the double bond has E configuration or Z configuration, pharmaceutically acceptable salt thereof, or a hydrate thereof.

[0031] More preferable compounds are shown below.

(A1) (5Z)-7-((1R, 2S, 3S, 4S)-3-(5-Hydroxybenzo[b]furan-3-yl)-1-
acid.

(A2) ((5Z)-7-((1R, 2S, 3S, 4S)-3-(Thiophen-3-carbonylamino)-bicyclo[2.2.1]hept-2-yl)-5-heptenoic acid,

(A3) (5Z)-7-((1R, 2S, 3S, 4S)-3-(Benzob[b]thiophen-7-yl)-cyclohept-2-enyl)-heptanoic acid, (5Z)-7-((1R, 2S, 3S, 4S)-3-(benzob[b]thiophen-7-yl)-cyclohept-2-enyl)-7-heptenoic acid, (5Z)-7-((1R, 2S, 3S, 4S)-3-(benzob[b]thiophen-7-yl)-cyclohept-2-enyl)-5-heptenoic acid,

(A4) (5Z)-7-((1R, 2S, 3S, 4S)-3-(Benzo(b)thiophen-3-carbonyl)amino)-2-
5 heptenoic acid, (E)-2-(2-hydroxy-2-methylpropyl)-5-heptenoic acid,

(A5) (5Z)-7-((1R, 2S, 3S, 4S)-3-(5-Fluorobenzo[b]thiophen-3-carbonyl)amino)-5-heptenoic acid


(A6) (5Z)-7-((1R, 2S, 3S, 4S)-3-(6-Hydroxybenzo[b]thiophen-3-carbonylamino)-3,5-dimethylhept-2-enyl)-5-heptenoic acid, or

30 acid, or
(A7) (5Z)-7-((1R, 2S, 3S, 4S)-3-(7-Hydroxybenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hept-2-yl)-5-heptenoic acid.

[0032] Examples of salts of the compounds (I) include those formed with an alkali metal (e.g. lithium, sodium, or potassium), an alkaline earth metal (e.g. calcium), an organic base (e.g. trimethamine, trimethylamine, triethylamine, 2-aminobutane, t-butylamine, diisopropylethylamine, n-butylmethylamine, cyclohexylamine, dicyclohexylamine, N-isopropylcyclohexylamine, furfurylamine, benzylamine, methylbenzylamine, dibenzylamine, N,N-dimethylbenzylamine, 2-chlorobenzylamine, 4-methoxybenzylamine, 1-naphthalenemethylamine, diphenylbenzylamine, triphenylamine, 1-naphthylamine, 1-aminoanthracene, 2-aminoanthracene, dehydroabiethylamine, N-methylmorpholine, or pyridine), an amino acid (e.g. lysine, or arginine), and the like.

[0033] "Hydrate" means a hydrate of the compound or the formula () of the compounds of the present invention are illustrated as follows.

45 [0034] General processes for the preparation of the compound.



(II) wherein R is an optionally substituted monocyclic or condensed heterocycle, provided that R is not an optionally substituted dibenzofuryl, X is hydrogen or an alkyl, and the double bond has E configuration or Z configuration.

[0035] As shown in the above process, the compound of the formula (I) can be prepared by reacting a carboxylic acid

EP 1 016 660 A1

of the formula (III) or the reactive derivative with an amino compound of the formula (II).

[0036] In this process, the starting compound (II) wherein X is a methyl, 7-(3-amino-bicyclo[2.2.1]hept-2-yl)-5-heptenoic acid methyl ester is described in the Japanese Patent Publication (KoKoku) No. 79060/1993. The other starting compounds can be prepared in accordance with methods as described in the above publication.

[0037] The carboxylic acid of the formula (III) includes thiophene-3-carboxylic acid, benzo[b]thiophene-7-carboxylic acid, benzo[b]thiophene-3-carboxylic acid, 5-fluorobenzo[b]thiophene-3-carboxylic acid, 5-hydroxybenzo[b]thiophene-3-carboxylic acid, 6-hydroxybenzo[b]thiophene-3-carboxylic acid, and the like.

[0038] These carboxylic acids can be prepared in accordance with methods as described in J. Org. Chem., 3 108-119 (1938), J. Med. Chem., Vol. 15, No. 4, 370-373 (1972), J. Heterocyclic Chem., 25, 1271-1272 (1988), HETEROCYCLES, Vol. 20, No. 10, 2035-2037 (1983), J. Med. Chem. 38, 3951-3956 (1995), or J. Chem. Soc., 2624-2630 (1957).

[0039] The reactive derivatives at the carboxylic acid of the formula (III) mean the corresponding acid halides (e.g., chloride, bromide, iodide), acid anhydrides (e.g., mixed acid anhydride with formic acid or acetic acid), active esters (e.g., succinimide ester), and the like, and include acylating agents used for the usual acylation of amino group. For example, an acid halide is obtained by reacting the compound (III) with a thionyl halide (e.g., thionyl chloride), phosphorous halide (e.g., phosphorous trichloride, phosphorous pentachloride), oxalyl halide (e.g., oxalyl chloride), and the like, in accordance with known methods as described in the literature (e.g., Shin-Jikken-Kagaku-Koza, Vol. 14, 1787 (1978); Synthesis 852-854 (1986); Shin-Jikken-Kagaku-Koza Vol. 22, 115 (1992)).

[0040] The reaction can be conducted under conditions generally used for the acylation of amino groups. For example, in the case of condensation with the acid halide, the reaction is carried out in a solvent such as an ether solvent (e.g., diethyl ether, tetrahydrofuran, dioxane), benzene solvent (e.g., benzene, toluene, xylene), halogenated hydrocarbon solvent (e.g., dichloromethane, dichloroethane, chloroform) as well as ethyl acetate, dimethylformamide, dimethyl sulfoxide, acetonitrile, or the like, if necessary, in the presence of a base (e.g., an organic base such as triethylamine, pyridine, N,N-dimethylaminopyridine, N-methylmorpholine; an inorganic base such as sodium hydroxide, potassium hydroxide, potassium carbonate, or the like) with cooling, at room temperature, or with heating, preferably at a temperature ranging from -20°C to ice-cooling temperature, or from a room temperature to the refluxing temperature of the reaction system, for a period of several minutes to several hours, preferably for 0.5 hr to 24 hr, particularly for 1 hr to 12 hr. When using the carboxylic acid in a free form without converting into the reactive derivatives, the reaction is conducted in the presence of a condensing agent (e.g., dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-methylaminopropyl)carbodiimide, N,N'-carbonyldiimidazole) usually used in the condensation reaction of an amine and carboxylic acid.

[0041] For example, in the case of the compound (III) wherein R is substituted with hydroxy or amino, the compound can be reacted after protecting with an acetyl group and the like in accordance with usual methods.

[0042] In the reaction of the other reactive derivatives or free acid with the amine (II), the reaction conditions are determined according to the property of each reactive derivative or free acid, in accordance with known methods. The reaction product can be purified in accordance with a conventional purification, such as extraction with a solvent, chromatography, recrystallization, and the like.

[0043] In case of the introduction of a substituent(s) into the "optionally substituted monocyclic or condensed heterocycle", the change of the functional group can be performed before or after reacting a carboxylic acid or the reactive derivative thereof (III) with the amine (II). For example, in the case of the compound having a monocyclic or condensed aromatic heterocycle, the compound having an aromatic heterocycle substituted with a nitro group can be obtained by nitration with a nitrating acid. Moreover, the compound having an aromatic heterocycle substituted with an amino group can be obtained by the reduction of the above compound with tin in the presence of hydrochloride. Moreover, the compound having an aromatic heterocycle substituted with a hydroxy group can be obtained by the diazotization of the above compound and hydrolysis with alkali. On the other hand, the compound having an aromatic heterocycle substituted with an alkoxy group can be obtained by the reaction of a diazonium derivative with alcohol. The compound having an aromatic heterocycle substituted with halogen can be obtained by Sandmeyer reaction, the reaction of the diazonium derivative with primary copper (e.g., CuCl₂, CuBr₂). The compound having an aromatic heterocycle substituted with halogen can be also obtained by the direct reaction of the compound having an aromatic heterocycle with chlorine and the like. Using the above-mentioned methods appropriately, halogen can be introduced into a desired position(s). The group alkyl, alkenyl, or acyl group can be directly introduced into an aromatic heterocycle by Friedel Crafts reaction with an alkyl agent an alkenyl agent or an acyl agent, respectively, in the presence of anhydrous aluminum chloride.

[0044] The objective compound (I) of the present invention can be converted into a corresponding ester derivative, if desired. For example, the ester derivative can be prepared by esterification of a carboxylic acid in accordance with a known method.

[0045] When using the compound (I) of the present invention in treatment, it can be formulated into ordinary formulations for oral and parenteral administration. A pharmaceutical composition containing the compound (I) of the present invention can be in the form for oral and parenteral administration. Specifically, it can be formulated into formulations for oral administration such as tablets, capsules, granules, powders, syrup, and the like; or those for

FP 1016 660 A1

EP 1 016 660 A1

parenteral administration such as injectable solution or suspension for intravenous, intramuscular, or subcutaneous injection, inhalant, eye drops, nasal drops, suppositories, or percutaneous formulations such as ointment.

[0046] In preparing the formulations, carriers, excipients, solvents, and bases known to one having ordinary skill in the art may be used. In the case of tablets, they are prepared by compressing or formulating an active ingredient together with auxiliary components, by compressing or formulating an active ingredient together with auxiliary components. Examples of usable auxiliary components include pharmaceutically acceptable excipients such as binders (e.g., cornstarch), fillers (e.g., lactose, microcrystalline cellulose), disintegrants (e.g., starch sodium glycolate) or lubricants (e.g., magnesium stearate). Tablets may be coated appropriately. In the case of liquid formulations such as syrups, solutions, or suspensions, they may contain suspending agents (e.g., methyl cellulose), emulsifiers (e.g. lecithin), preservatives, and the like. In the case of injectable formulations, they may be in the form of solution, suspension, or oily or aqueous emulsion, which may contain suspension-stabilizing agents or dispersing agents, and the like. In the case of an inhalant, they are formulated into a liquid formulation applicable to an inhaler. In the case of eye drops, they are formulated into a solution or a suspension. Especially, in the case of a nasal drug for treating nasal blockage, it can be used as a solution or suspension prepared by a conventional formulating method, or administered as a powder formulated using a powdering agent (e.g., hydroxypropyl cellulose, carbopole) into the nasal cavity. Alternatively, it can be used as an aerosol filled into a special container together with a solvent of low boiling point.



[0047] Although an appropriate dosage of the compound (I) varies depending on the administration route, age, body weight, sex, or condition of the patient, and the kind of drug(s) used together, if any, and should be finally determined by the physician. In the case of oral administration, the daily dosage can generally be between 0.01 - 100 mg, preferably 0.01 - 10 mg, more preferably 0.01 - 1 mg. per kg body weight. In the case of parenteral administration, the daily dosage can generally be between 0.001- 100 mg, preferably 0.001- 1 mg, more preferably 0.001 - 0.1 mg, per kg body weight. The daily dosage can be administered in 1 - 4 parts.

[0048] The following examples are provided to further illustrate the present invention and are not to be construed as limiting the scope.

25 Example 1

Example 1
Preparation of (5Z)-7-((1R, 2S, 3S, 4S)-3-(5-Hydroxybenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hept-2-yl)-5-heptanoic acid (1)

30



(Step 1)

(Step 1)

[0050] To a solution of 251 mg (1.0 mmol) of amino compound (1-a) (described in Japanese Patent Publication (Kokoku No.79060/1993) in 5 ml of tetrahydrofuran were added 0.5 ml (3.6 mmol) of triethylamine and 255 mg (1.0 mmol) of 5-acetoxybenzo[b]thiophen-3-carbonyl chloride. After stirring for 1 hour, the mixture was diluted with water, and extracted with toluene. The organic layer was washed with dilute hydrochloric acid and water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was chromatographed on silica gel (toluene : ethyl acetate = 9 : 1) to give 420 mg of the compound (1-b). Yield 89.4 %.

[0051] The obtained compound was recrystallized from ethyl acetate and n-hexane (1 : 3) to give 304 mg of needle crystals. Yield 64.7 %. M.p. 87-88 °C.

5 [α]_D²⁶ +51.8° (c = 1.01 %, CH₃OH)

Elementary Analysis (for C ₂₆ H ₃₁ NO ₅ S)				
Calcd.(%):	C, 66.50;	H, 6.65;	N, 2.98;	S, 6.83
Found(%):	C, 66.46;	H, 6.67;	N, 3.01;	S, 6.95

10

(Step 2)

15 [0052] To a solution of 332 mg (0.71 mmol) of the above obtained compound (1-b) in 3 ml of methanol was added 0.61 ml (2.5 mmol) of 4N sodium hydroxide. After stirring for 2 hours at 42 °C, the reaction mixture was neutralized with 2.5 ml of 1N hydrochloric acid, diluted with water, and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate / n-hexane (1 : 3) to give 250 mg of the compound (1) as needles. Yield (%) 85.6 %. Mp 140 - 141.5 °C.

20

[α]_D²⁵ +57.3° (c = 1.00 %, CH₃OH)

Elementary Analysis (for C ₂₃ H ₂₇ NO ₄ S)				
Calcd.(%):	C, 66.80;	H, 6.58;	N, 3.39;	S, 7.75
Found(%):	C, 66.57;	H, 6.56;	N, 3.28;	S, 7.59

30

¹H NMR δ (CDCl₃), 300MHz; 1.09 (1H, m), 1.20-1.34 (2H, m), 1.45-1.54 (2H, m), 1.57-1.70 (4H, m), 1.96-2.32 (7H, m), 2.61 (1H, s), 3.90 (1H, m), 5.26-5.46 (2H, m), 6.25 (1H, d, J = 7.2 Hz), 7.01 (1H, dd, J = 2.4 and 8.7 Hz), 7.65 (1H, d, J = 8.7 Hz), 7.79 (1H, s), 8.04 (1H, d, J = 2.4 Hz).

35

IR (Nujol); 3305, 3107, 3066, 2925, 2853, 2710, 2635, 1713, 1626, 1601, 1550 cm⁻¹

Example 2 - 17


40

[0053] The following compounds were prepared in the same manner as Example 1 except for using another acid chloride as a starting material.

45

50

55



5	Compd. No.	R	Compd. No.	R
10	2		10	
15	3		11	
20	4		12	
25	5		13	
30	6		14	
35	7		15	
40	8		16	
45	9		17	

55 Compd. 2

[0054]

EP 1016 660 A1

5 ^1H NMR δ (CDCl₃), 300MHz: 1.08 (1H, m), 1.20-1.30 (2H, m), 1.45-1.50 (2H, m), 1.58-1.80 (4H, m), 2.03-2.23 (5H, m), 2.36 (2H, t, J = 7.2 Hz), 2.55 (1H, s), 3.85 (1H, m), 5.31-5.45 (2H, m), 6.13 (1H, d, J = 6.3 Hz), 7.33 (1H, dd, J = 3.0 and 5.1 Hz), 7.39 (1H, dd, J = 1.2 and 5.1Hz), 7.88(1H, dd, J = 1.2 and 3.0 Hz)

10 IR (CHCl₃): 3447, 3114, 3022, 3016, 2955, 2877, 2665, 1708, 1650, 1536, 1498 cm⁻¹

[α]_D²⁵ +75.3° (c = 1.02 %, CH₃OH)

15 Compd. 3

[0055]

20 ^1H NMR δ (CDCl₃), 300MHz; 1.15 (1H, m), 1.26-1.34 (2H, m), 1.45-1.56 (2H, m), 1.61-1.77 (4H, m), 2.05-2.27 (5H, m), 2.37 (2H, t, J = 7.4 Hz), 2.64 (1H, m), 3.99 (1 H, m), 5.31-5.47 (2H, m), 6.45 (1H, d, J = 7.5 Hz), 7.38 (1H, d, J = 5.4 Hz), 7.42 (1H, t, J = 7.8 Hz), 7.59 (1H, d, J = 5.4 Hz), 7.63 (1H, m), 7.96 (1H, dd, J = 0.9 and 7.8 Hz).

25 IR (CHCl₃): 3453, 3117, 3063, 3031, 3017, 3012, 2955, 2876, 2669, 1708, 1650, 1585, 1567, 1519, 1495 cm⁻¹

[α]_D²⁵ +62.8° (c = 1.00 %, CH₃OH)

30 Compd. 4

[0056]

35 ^1H NMR δ (CDCl₃), 300MHz; 1.11 (1H, m), 1.22-1.34 (2H, m), 1.48-1.53 (2H, m), 1.60-1.78 (4H, m), 2.04-2.27 (5H, m), 2.36 (2H, t, J = 7.2 Hz), 2.62 (1H, m), 3.94 (1 H, m), 5.33-5.48 (2H, m), 6.16 (1H, d, J = 7.2 Hz), 7.39 (1H, m), 7.46 (1H, m), 7.86 (1H, m), 7.88 (1H, s), 8.31 (1H, d, J = 7.5 Hz).

40 IR (CHCl₃): 3439, 3066, 3025, 3013, 2955, 2876, 2670, 1707, 1652, 1516, 1493 cm⁻¹

[α]_D²⁵ +62.7° (c = 1.01 %, CH₃OH)

45 Compd. 5

[0057]

50 ^1H NMR δ (CDCl₃), 300MHz; 1.08 (1H, m), 1.20-1.34 (2H, m), 1.45-1.54 (2H, m), 1.56-1.78 (4H, m), 2.03-2.24 (5H, m), 2.36 (2H, t, J = 7.2 Hz), 2.61 (1H, s), 3.92 (1H, m), 5.31-5.50 (2H, m), 6.17 (1H, d, J = 7.8 Hz), 7.15 (1H, dt, J = 2.7 and 8.7 Hz), 7.77 (1H, dd, J = 4.8 and 8.7 Hz) 7.92 (1H, s), 8.06 (1H, dd, J = 2.7 and 10.2 Hz).

55 IR (CHCl₃): 3517, 3439, 3094, 3023, 3015, 2955, 2876, 2669, 1708, 1654, 1603, 1566, 1515 cm⁻¹

[α]_D²⁴ +60.6° (c = 1.00 %, CH₃OH)

60 Compd. 6

[0058]

65 ^1H NMR δ (CDCl₃), 300MHz; 1.08 (1H, m), 1.20-1.34 (2H, m), 1.46-1.53 (2H, m), 1.60-1.80 (4H, m), 2.00-2.37 (7H, m), 2.61 (1H, s), 3.91 (1H, m), 5.33-5.46 (2H, m), 6.16 (1H, d, J = 8.1 Hz), 6.99 (1H; dd, J = 2.4 and 8.7 Hz), 7.28 (1H, d, J = 2.4 Hz), 7.65 (1H, s), 8.13 (1H, d, J = 8.7 Hz).

EP 1016 660 A1

IR (CHCl₃): 3598, 3510, 3437, 3101, 3029, 3017, 3006, 2955, 2876, 1709, 1646, 1603, 1559, 1518 cm⁻¹

[α]_D²⁴ +61.2° (c = 1.01 %, CH₃OH)

5

Compd. 7

[0059]

10

¹H NMR δ (CDCl₃), 300MHz; 1.18 (1H, m), 1.30-1.33 (2H, m), 1.48-1.80 (6H, m), 1.53 (9H, s), 2.03-2.40 (7H, m), 2.07 (1H, m), 3.91 (1H, m), 5.31-5.51 (2H, m), 6.23 (1H, d, J = 7.8 Hz), 7.50 (1H, dd, J = 1.8 and 7.8 Hz), 7.75 (1H, d, J = 7.8 Hz), 8.25 (1H, m)

15

IR (CHCl₃): 3437, 3102, 3023, 3015, 2956, 2876, 1711, 1651, 1607, 1568, 1509 cm⁻¹

[α]_D²³ +39.5° (c = 1.00 %, CH₃OH)

20

Compd. 8

[0060]

25

¹H NMR δ (CDCl₃), 300MHz; 1.12 (1H, m), 1.22-1.33 (2H, m), 1.42-1.54 (2H, m), 1.61-1.76 (4H, m), 2.01-2.33 (5H, m), 2.40 (2H, t, J = 7.2 Hz), 2.57 (1H, m), 2.96 (3H, s), 3.91 (1H, m), 5.31-5.47 (2H, m), 6.19 (1H, d, J = 7.2 Hz), 7.51 (1H, dd, J = 2.4 and 9.0 Hz), 7.81 (1H, d, J = 9.0 Hz), 7.88 (1H, s), 8.20 (1H, d, J = 2.4 Hz)

30

IR (CHCl₃): 3509, 3438, 3366, 3223, 3100, 3031, 3017, 3023, 3017, 3012, 2955, 2876, 1709, 1645, 1606, 1518, 1475, 1329 cm⁻¹

[α]_D²⁵ +42.3° (c = 1.01 %, CH₃OH)

35

Compd. 9

[0061]

40

¹H NMR δ (CDCl₃), 300MHz; 1.15 (1H, m), 1.22-1.34 (2H, m), 1.33 (3H, t, J = 7.2 Hz), 1.49-1.55 (2H, m), 1.61-1.82 (4H, m), 2.05-2.14 (5H, m), 2.39 (2H, t, J = 7.2 Hz), 2.59 (1H, m), 3.91 (1H, m), 4.25 (2H, q, J = 7.2 Hz), 5.33-5.48 (2H, m), 6.21 (1H, d, J = 7.2 Hz), 7.62 (1H, dd, J = 1.8 and 8.7 Hz), 7.77 (1H, d, J = 8.7 Hz), 7.89 (1H, s), 8.22 (1H, m)

45

IR (CHCl₃): 3436, 3101, 3030, 3023, 3014, 2956, 2876, 1728, 1650, 1608, 1570, 1515, 1440 cm⁻¹

[α]_D²⁵ +41.8° (c = 1.00 %, CH₃OH)

50

Compd. 10

[0062]

55

¹H NMR δ (CD₃OD), 300MHz; 1.30-1.71 (9H, m), 2.02-2.22 (7H, m), 2.55 (1H, m), 3.82 (1H, m), 5.41-5.44 (2H, m), 6.88 (1H, dd, J = 2.4 and 8.7 Hz), 7.60 (1H, d, J = 8.7 Hz), 7.63 (1H, d, J = 2.4 Hz), 8.02 (1H, s)

IR (Nujol); 3307, 1624, 1532 cm⁻¹

[α]_D²³ +32.6° (c = 1.00 %, CH₃OH)

Compd. 11

5 [0063]

¹H NMR δ (CDCl₃, 300MHz; 1.11 (1H, m), 1.22-1.31 (2H, m), 1.45-1.54 (2H, m), 1.60-1.79 (4H, m), 2.03-2.26 (5H, m), 2.36 (2H, t, J = 7.2 Hz), 2.57 (1H, m), 3.88 (1H, m), 4.00 (3H, s), 5.31-5.45 (2H, m), 6.22 (1H, d, J = 7.2 Hz), 6.84 (1H, d, J = 7.5 Hz), 7.34 (1H, dd, J = 7.5 and 8.1 Hz), 7.44 (1H, d, J = 8.1 Hz), 7.79 (1H, s)

10 IR (CHCl₃): 3444, 3422, 3065, 3024, 3018, 3015, 2956, 2877, 2841, 2669, 1708, 1650, 1570, 1542, 1503, 1471 cm⁻¹

15 [α]_D²¹ +91.6° (c = 1.00 %, CH₃OH)

Compd. 12

20 [0064]

¹H NMR δ (CDCl₃ / CD₃OD), 300MHz; 1.16 (1H, m), 1.28-1.31 (2H, m), 1.46-1.53 (2H, m), 1.60-1.74 (4H, m), 2.04-2.22 (5H, m), 2.32 (2H, t, J = 7.4 Hz), 2.57 (1H, m), 3.87 (1H, m), 5.32-5.46 (2H, m), 6.48 (1H, d, J = 7.2 Hz), 6.84 (1H, d, J = 7.5 Hz), 7.23 (1H, dd, J = 7.5 and 8.1 Hz), 7.37 (1H, d, J = 8.1 Hz), 7.79 (1H, s)

25 [α]_D²² +44.2° (c = 1.00 %, CH₃OH)

Compd. 13

30 [0065]

¹H NMR δ (CDCl₃, 300MHz; 1.14 (1H, m), 1.26-1.34 (2H, m), 1.46-1.53 (2H, m), 1.60-1.79 (4H, m), 2.03-2.25 (5H, m), 2.36 (2H, t, J = 7.2 Hz), 2.41 (3H, s), 2.57 (1H, m), 3.88 (1H, m), 5.31-5.46 (2H, m), 6.25 (1H, d, J = 7.2 Hz), 7.23 (1H, d, J = 7.5 Hz), 7.40 (1H, dd, J = 7.5 and 7.8 Hz), 7.69 (1H, d, J = 7.8 Hz), 7.78 (1H, s)

35 IR (CHCl₃): 3443, 3422, 3030, 3010, 2955, 2877, 1756, 1708, 1650, 1564, 1540, 1504 cm⁻¹

40 [α]_D²² +85.6° (c = 1.00 %, CH₃OH)

Compd. 14

45 [0066]

¹H NMR δ (CDCl₃, 300MHz; 1.11 (1H, m), 1.23-1.32 (2H, m), 1.42-1.59 (2H, m), 1.60-1.82 (3H, m), 2.04-2.31 (6H, m), 2.37 (2H, t, J = 7.2 Hz), 2.56 (1H, m), 3.93 (1H, m), 4.01 (3H, s), 5.30-5.45 (2H, m), 6.74 (1H, m), 7.13 (1H, s), 7.70 (1H, d, J = 2.1 Hz), 8.26 (1H, d, J = 7.2 Hz), 8.36 (1H, d, J = 0.6 Hz)

50 IR (CHCl₃): 3397, 3026, 3015, 2955, 2877, 2654, 1709, 1642, 1623, 1538, 1475, 1459 cm⁻¹

$[\alpha]$ _D²³ +66.7° (c = 1.00 %, CH₃OH)

55 Compd. 15

[0067]

5 ^1H NMR δ (CDCl_3), 300MHz; 1.12 (1H, m), 1.26-1.29 (2H, m), 1.46-1.50 (2H, m), 1.57-1.78 (4H, m), 2.05-2.25 (5H, m), 2.38 (2H, t, $J = 7.4$ Hz), 2.53 (1H, m), 3.82 (3 H, s), 3.88 (1H, m), 5.32-5.45 (2H, m), 6.35 (1H, d, $J = 7.5$ Hz), 6.80 (1H, d, $J = 2.1$ Hz), 6.91 (1H, dd, $J = 2.1$ and 9.0 Hz), 7.01 (1H, d, $J = 2.1$ Hz), 7.35 (1H, d, $J = 9.0$ Hz), 10.25 (1H, s)

10 IR (CHCl_3): 3446, 3242, 3022, 3012, 2955, 2877, 2834, 2654, 1707, 1626, 1586, 1541, 1507, 1480 cm^{-1}

15 $[\alpha]_D^{23} +109.1^\circ$ ($c = 1.01$ %, CH_3OH)

Compd. 16

[0068]

20 ^1H NMR δ ($\text{CDCl}_3 / \text{CD}_3\text{OD}$), 300MHz; 1.17 (1H, m), 1.29-1.32 (2H, m), 1.45-1.74 (6H, m), 2.04-2.22 (5H, m), 2.32 (2H, t, $J = 7.4$ Hz), 2.57 (1H, m), 3.88 (1H, m), 5.32-5.49 (2H, m), 6.38 (1H, d, $J = 6.6$ Hz), 6.82 (1H, dd, $J = 2.4$ and 8.7 Hz), 7.26 (1H, d, $J = 8.7$ Hz), 7.34 (1H, d, $J = 2.4$ Hz), 7.73 (1H, s), 10.27 (1H, s)

25 IR (KBr): 3287, 3306, 2951, 2873, 2634, 1708, 1599, 1539, 1501, 1469, 1432 cm^{-1}

30 $[\alpha]_D^{26} +52.3^\circ$ ($c = 1.01$ %, CH_3OH)

Compd. 17

[0069]

35 ^1H NMR δ (CDCl_3), 300MHz; 1.14 (1H, m), 1.26-1.31 (2H, m), 1.46-1.78 (6H, m), 2.01-2.28 (5H, m), 2.33 (2H, t, $J = 7.2$ Hz), 2.58 (1H, m), 3.84 (3H, s), 3.91 (1H, m), 5.27-5.47 (2H, m), 6.21 (1H, d, $J = 7.5$ Hz), 6.87 (1H, dd, $J = 2.4$ and 9.3 Hz), 7.28 (1H, d, $J = 2.1$ and 9.0 Hz), 7.41 (1H, d, $J = 2.4$ Hz), 7.72 (1H, d, $J = 2.4$ Hz), 9.54 (1H, s)


40 IR (CHCl_3): 3466, 3193, 3033, 3014, 2954, 2876, 2835, 2664, 1709, 1627, 1586, 1637, 1503, 1439 cm^{-1}

45 $[\alpha]_D^{26} +44.3^\circ$ ($c = 1.01$ %, CH_3OH)

Example 18

Preparation of (5Z)-7-((1S,2R,3R,4R)-3-(5-Hydroxybenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hept-2-yl)-5-heptenoic acid (18)

[0070]



55 [0071] The compound 18 was prepared in the same manner as Example 1 except for using another compound as an amino compound.

Compd. 18

[0072]

¹H NMR δ (CDCl₃), 300MHz; 1.09 (1H, m), 1.20-1.34 (2H, m), 1.45-1.54 (2H, m), 1.57-1.70 (4H, m), 1.96-2.32 (7H, m), 2.61 (1H, s), 3.90 (1H, m), 5.26-5.46 (2H, m), 6.19 (1H, d, J = 6.9 Hz), 7.02 (1H, dd, J = 2.4 and 8.7 Hz), 7.67 (1H, d, J = 8.7 Hz), 7.79 (1H, s), 8.04 (1H, d, J = 2.4 Hz).

IR (Nujol); 3306, 3105, 3060, 2925, 2853, 2710, 2635, 1713, 1627, 1601, 1550 cm⁻¹

[α]_D²⁵-57.3° (c = 1.01 %, CH₃OH). Mp 141-142.5 °C

[0073] The compounds prepared in Examples above were tested for determining the in vivo and in vitro activities according to the method as shown in the Experimental examples below.

Experiment 1Binding to PGD₂ Receptor

(1) Preparation of Human Platelet Membrane Fraction

[0074] Blood was collected using a plastic syringe containing 3.8 % sodium citrate from the vein of healthy volunteers (adult male and female), then put into a plastic test tube and mixed by slow-reversion. The sample was then centrifuged at 1800 rpm, for 10 min at room temperature, and the supernatant containing PRP (platelet-rich plasma) was collected. The PRP was re-centrifuged at 2300 rpm, for 22 min at room temperature to obtain platelets. The platelets were homogenized using a homogenizer (Ultra-Turrax) followed by centrifugation 3 times at 20,000 rpm, 10 min at 4 °C to obtain a platelet membrane fraction. After protein determination, the membrane fraction was adjusted to 2 mg/ml and preserved in a refrigerator at -80°C until used for the binding test (2) Binding to PGD₂ Receptor

[0075] To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 5 mM MgCl₂) (0.2 ml) were added the human platelet membrane fraction (0.1 mg) and 5 nM [³H]PGD₂ (115 Ci/mmol), and the mixture was reacted at 4 °C for 90 min. After the reaction, the mixture was filtered through a glass fiber filter paper and washed several times with cooled physiological saline, then the radioactivity retained on the filter paper was measured. The specific-binding ratio was calculated by subtracting the non-specific binding ratio which is the radioactivity similarly measured in the presence of 10 μM PGD₂ from the total binding. The inhibitory activity of each compound was expressed as the concentration required for 50 % inhibition (IC₅₀), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100%. The results are shown below.

Compd. No.	Inhibitory activity IC ₅₀ (μM)
1	0.0096
2	0.0310
3	0.0870
4	0.0082
5	0.0570
6	0.1800
18	0.0055

Experiment 2Evaluation of Antagonistic Activity Against PGD₂ Receptor Using Human Platelets

EP 1 016 660 A1

[0076] Peripheral blood was collected from a healthy volunteer using a syringe in which 1/9 volume of a citric acid/dextrose solution was previously added. The sample was subjected to centrifugation at 180 g for 10 min to obtain the supernatant (PRP: platelet rich plasma). The resultant PRP was washed 3 times with a washing buffer and the number of platelets was counted with a micro cell counter. A suspension adjusted to contain the platelets at a final concentration of $5 \times 10^8/\text{ml}$ was warmed at 37 °C, then subjected to the pre-treatment with 3-isobutyl-1-methylxanthine (0.5 mM) for 5 min. To the suspension was added a test compound diluted at various concentrations, and 10 minutes later, 0.1 μM PGD₂ was added to induce the reaction 2 minutes later. Hydrochloric acid was added to terminate the reaction. The platelets were destroyed with an ultrasonic homogenizer. After centrifugation, the cAMP in the supernatant was determined by radioimmunoassay. PGD₂ receptor antagonism of a drug was evaluated as follows: the inhibition rate regarding cAMP increased by the addition of PGD₂ was determined at each concentration, and the concentration of the drug required for 50 % inhibition (IC₅₀) was calculated. The results are shown below.

Compd. No.	IC ₅₀ (μM)
1	0.0039
2	0.3600
3	0.0220
4	0.0410
5	0.0340
6	0.0082
18	>1.0000

Experiment 3

Experiment Using Nasal Blockage Model

[0077] Recently, attention has been paid to a theory that PGD₂ is one of the causative substances of nasal blockage caused by allergic rhinitis, and it has been proposed to develop an inhibitor of PGD₂ biosynthesis or an antagonist to the PGD₂ receptor as a drug reducing nasal blockage. Thus, as to the compounds of the present invention, the anti-nasal blockage effect was evaluated by measuring the intranasal pressure of guinea pigs.

[0078] A 1% ovalbumin (OVA) solution was treated with an ultrasonic nebulizer to obtain an aerosol. A Hartley male guinea pig was sensitized by inhaling the aerosol twice each or 10 min at one-week interval. Seven days after the sensitization, the guinea pig was exposed to an antigen to initiate the reaction. Briefly, the trachea of the guinea pig was incised under anesthesia with pentobarbital (30 mg/kg, i.p.) and cannulas were inserted into the trachea at the pulmonary and nasal cavity sides. The canal inserted at the pulmonary side was connected with an artificial respirator that provides 4 ml/time of air 60 times/min. After arresting the spontaneous respiration of the guinea pig with Gallamin (2 mg/kg, i.v.), 4 ml/time of air was supplied to the snout side with an artificial respirator at the frequency of 70 times/min, and the atmospheric pressure required for the aeration was measured by using a transducer fitted at the branch. The measured pressure was used as a parameter of the nasal cavity resistance. The exposure of an antigen was carried out by generating the aerosol of 3 % OVA solution for 3 min between the respirator and the nasal cavity cannula. The test drug (30 mg/kg) was administered orally 60 min before the antigen exposure. The intranasal pressure between 0 to 30 min was measured continuously and the effect was expressed as an inhibition rate to that obtained for a vehicle using the AUC for 30 min (on the vertical axis, intranasal pressure (cm H₂O), and on the horizontal axis, time (0-30 min)) as an indication. The result is shown below.

Compd. No.	Inhibitory Rate (%)
1	74

Experiment 4

Binding to TXA₂ Receptor

(1) Preparation of Human Platelet Membrane Fraction

5 [0079] The human platelet fraction was prepared in accordance with Experiment 1 (1).


(2) Binding to TXA₂ Receptor

10 [0080] To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 10 mM MgCl₂) (0.2 ml) were added the human platelet membrane fraction (0.05 mg) and 2 nM Sodium [³H](+)-(5Z)-7-[3-endo-[phenylsulfonyl]amino]bicyclo[2.2.1]hept-2-exo-iy]heptenoate (Japanese Patent Publication (Kokoku) No.79060/1993, hereinafter referred to as (+)-S-145 sodium salt) (26.4 Ci/mmol), and the mixture was reacted at room temperature for 90 min. After the reaction, the resultant mixture was filtered through a glass fiber filter paper and washed several times with cooled physiological saline, then the radioactivity retained on the filter paper was measured. The specific-binding ratio was calculated by subtracting the non-specific binding ratio (the radioactivity similarly determined in the presence of 10 μM (+)-S-145 sodium salt) from the total binding. The inhibitory activity of each compound was expressed as the concentration required for 50 % inhibition (IC₅₀), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100 %. The results are shown below.

Compd. No.	Inhibitory activity to TXA ₂ Receptor: IC ₅₀ (μM)
1	0.15
4	3.8
18	1.8


Claims

- 30 1. A compound of the formula (I):




35 wherein R is an optionally substituted monocyclic or condensed heterocycle, provided that R is not an optionally substituted dibenzofuryl, X is hydrogen or an alkyl, and the double bond has E configuration or Z configuration, a pharmaceutically acceptable salt thereof or a hydrate thereof.

- 40 2. The compound according to claim 1 wherein R is a monocyclic or condensed heterocycle optionally substituted with an alkyl, an alkenyl, an acyl, an alkoxy, an alkylthio, an acyloxy, hydroxy, a halogen, nitro, or substituted or unsubstituted amino, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- 45 3. The compound according to claim 1 wherein R is an optionally substituted monocyclic or condensed heterocycle containing only a sulfur atom(s) as hetero atom, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- 50 4. The compound according to claim 1 wherein R is a monocyclic or condensed heterocycle containing only a sulfur atom(s) as hetero atom and optionally substituted with an alkyl, an alkenyl, an acyl, an alkoxy, an alkylthio, an acyloxy, hydroxy, a halogen, nitro, or substituted or unsubstituted amino, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- 55 5. The compound according to claim 1 wherein R is a group of the formula:



5



10

wherein Y and Z each is independently hydrogen, hydroxy, or a halogen, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

6. The compound according to claim 1 wherein said compound is

20 (A1) (5Z)-7-((1R, 2S, 3S, 4S)-3-(5-Hydroxybenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid,

(A2) ((5Z)-7-((1R, 2S, 3S, 4)-3-(Thiophen-3-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid,

25 (A3) (5Z)-7-((1R, 2S, 3S, 4S)-3-(Benzo[b]thiophen-7-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid,

(A4) (5Z)-7-((1R, 2S, 3S, 4S)-3-(Benzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid,

30 (A5) (5Z)-7-((1R, 2S, 3S, 4S)-3-(5-Fluorobenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid,

(A6) (5Z)-7-((1R, 2S, 3S, 4S)-3-(6-Hydroxybenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid, or

35 (A7) (5Z)-7-((1R, 2S, 3S, 4S)-3-(7-Hydroxybenzo[b]thiophen-3-carbonylamino)-bicyclo[2.2.1]hepto-2-yl)-5-heptenoic acid, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

7. A pharmaceutical composition comprising the compound according to any one of claims 1-6, a pharmaceutically acceptable salt thereof, or a hydrate thereof

40 8. The pharmaceutical composition according to claim 7 wherein said pharmaceutical composition is antagonistic to both TXA₂ and PGD₂.

45 9. The pharmaceutical composition according to claim 7 which is for treating asthma.

10. The pharmaceutical composition according to claim 7 which is for treating nasal blockage.

50 11. Use of the compound salt or hydrate according to any one of claims 1-6 for the preparation of the pharmaceutical composition for treating asthma or nasal blockage.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/03991

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl' C07D209/42, 307/79, 333/38, 333/68, A61K31/34, 38, 40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl' C07D209/42, 307/79, 333/38, 333/68, A61K31/34, 38, 40

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CA, REGISTRY (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ARIMURA A. et al., "Antiasthmotic Activity of a Novel Thromboxane A2 Antagonist, S-1452, in Guinea Pigs", Int. Arch. Allergy Immunol., (1992), 98(3), p.239-46	1-11
P, A	TSURI T. et al., "Bicyclo[2.2.1]heptane and 6,6-Dimethylbicyclo[3.3.1]heptane Derivatives: Orally Active, Potent, and Selective Prostaglandin D2 Receptor Antagonist", J. Med. Chem., (1997), 40(22), p.3504-7	1-11

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document but published on or after the international filing date	X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	& document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 16 November, 1998 (16. 11. 98)	Date of mailing of the international search report 24 November, 1998 (24. 11. 98)
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer
Facsimile No.	Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)